The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
 
Linda Duska
Consulting or Advisory Role - Ellipses Pharma (Inst); Inovio Pharmaceuticals; Merck (Inst); Regeneron
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Editor, British Journal of Ob/Gyn; UpToDate
 
Yang Xiang
No Relationships to Disclose
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Kyowa Kirin; MSD K.K; Regeneron; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; Merck KGaA; MSD K.K; Regeneron; Roche; Sanofi; Takeda; Zymeworks
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Pier Ramos-Elias
Honoraria - Asofarma; AstraZeneca; MSD; MSD
Consulting or Advisory Role - Asofarma
Speakers' Bureau - Asofarma; AstraZeneca; MSD; Novartis
Research Funding - MSD; Roche/Genentech; Zymeworks
Travel, Accommodations, Expenses - Asofarma; AstraZeneca; Janssen; Pfizer; Roche/Genentech
 
Paolo Rodolfo Valdez Barreto
No Relationships to Disclose
 
Alejandro Acevedo
No Relationships to Disclose
 
Felipe Cruz
Consulting or Advisory Role - Pfizer, Bayer, Astellas Pharma,Janssen
Travel, Accommodations, Expenses - Janssen Oncology, Novartis
 
Valeria Saevets
No Relationships to Disclose
 
Rudolf Lampé
No Relationships to Disclose
 
Limor Helpman
No Relationships to Disclose
 
Jalid Sehouli
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Clovis Oncology; Corcept Therapeutics; Daiichi; Eisai; Esteve Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Hexal; Incyte; Jenapharm; Johnson & Johnson; Kyowa Kirin International; Medtronic Covidien; MSD Oncology; Myriad Pharmaceuticals; Novartis; Oncoinvent; Pfizer; PharmaMar; Phytolife Nutrition; Roche; Vifor Pharma
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer/Vital; Bristol Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Eisai; GlaxoSmithKline; Immunogen; Ingress Health; Intuitive Surgical; Johnson & Johnson; Karyopharm Therapeutics; Lilly; Merck; MSD Oncology; Mundipharma; Novocure; Oncoinvent; Pfizer; PharmaMar; Roche; Sanofi Aventis GmbH; Seagen; Sobi; Tubulis GmbH
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); IQvia (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); MSD Oncology (Inst); Mural (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG
 
Flora Zagouri
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD; Novartis; Pfizer Hellas; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
 
Yong Man Kim
Honoraria - MSD
Consulting or Advisory Role - Genentech
Research Funding - AstraZeneca (Inst); Immunogen (Inst); MorphoSys (Inst); MSD (Inst); Regeneron (Inst)
 
Peng Liu
Employment - Merck
 
Karin Yamada
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Sarper Toker
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sandro Pignata
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; Novartis; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO
 
on behalf of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 Investigators
No Relationships to Disclose